Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in cervical and other gynecologic cancers
- Trial result
Cervical and other gynecologic cancers
Pembrolizumab (PD-1) + Chemotherapy Sustains 5-Year OS Benefit in 1L Advanced Cervical Cancer
Pembrolizumab is a PD-1–blocking antibody added to platinum–taxane chemotherapy, with or without bevacizumab, for previously untreated persistent, recurrent, or metastatic cervical cancer; in the US, this combination…
- New trial Spotlight
Cervical and other gynecologic cancers
Phase 2 tisotumab vedotin (tissue factor–targeted) MMAE ADC in recurrent/metastatic vulvar SCC.
This open-label, single-arm Phase 2 study sponsored by the GOG Foundation evaluates tisotumab vedotin in recurrent or metastatic vulvar squamous cell carcinoma, with objective response rate as the primary efficacy…
NCT07672782 Exploratory - Trial result
Cervical and other gynecologic cancers
Hypofractionated pelvic RT (37.5Gy/15fx) + weekly cisplatin shows similar pCR vs standard 50Gy/25fx in LACC surgery cohort
Phase II randomized trial (NCT03750539) in FIGO IB3–IIIC1 locally advanced cervical cancer tested concurrent weekly cisplatin with either standard-fractionation EBRT (50Gy/25fx) or hypofractionated EBRT…
NCT03750539 - Trial result
Cervical and other gynecologic cancers
CRB-701 (SYS6002) Nectin-4–targeted MMAE ADC shows early ~38% unconfirmed ORR in R/M cervical cancer
CRB-701 is a next-generation Nectin-4–targeting antibody–drug conjugate (ADC) delivering MMAE, evaluated in a Phase 1/2 dose-escalation/optimization study (NCT06265727) in recurrent/metastatic cervical cancer after…
NCT06265727 - Trial result
Cervical and other gynecologic cancers
Camrelizumab (PD-1) + cisplatin/nab-paclitaxel hits 100% ORR and 30% pCR in PD-L1–negative LACC
Camrelizumab is an anti–PD-1 antibody tested here as neoadjuvant chemo-immunotherapy (NACI) with cisplatin + nab-paclitaxel in a multicenter, open-label, single-arm Phase 2 trial in treatment-naïve, PD-L1–negative…
NCT06288360 - Trial result Spotlight
Cervical and other gynecologic cancers
T-DXd (HER2 ADC) drives ~45–58% ORR in pretreated HER2-expressing endometrial / cervical / ovarian cancers
Trastuzumab deruxtecan (T-DXd; Enhertu) is a HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload, evaluated at 5.4mg/kg in the open-label Phase 2 DESTINY-PanTumor02 study…
NCT04482309 - Trial result
Cervical and other gynecologic cancers
Tisotumab vedotin (tissue factor ADC) triplet with pembrolizumab + carbo pushes 65.8% ORR (1L r/mCC) but with heavy discontinuations
Tisotumab vedotin (TV) is a tissue factor–directed antibody–drug conjugate delivering MMAE; in innovaTV 205/ENGOT-cx8/GOG-3024 (Phase 1b/2; NCT03786081), TV was combined with carboplatin (arm D, 1L; n=33) or…
NCT03786081 - New trial
Cervical and other gynecologic cancers
Phase I pBI-11 HPV16/18 DNA vaccine ± TA-HPV immunotherapy in advanced disease
Johns Hopkins (SKCCC) randomizes adjuvant PVX7 regimens using pBI-11 (therapeutic DNA vaccine to HPV16/18 from Papivax) via scarification or IM, with/without TA-HPV. After chemo/IO for recurrent/metastatic disease,…
NCT06315257 Exploratory - Trial result
Cervical and other gynecologic cancers
HPV16 L2/E7/E6 Vaccine (TA-CIN): Thigh Injection Yields Stronger Immunity Post-Treatment
TA-CIN is a recombinant HPV16 L2/E7/E6 fusion-protein therapeutic vaccine; in a randomized pilot (NCT02405221), 15 HPV16+ cervical cancer patients with no evidence of disease after primary therapy (stage IB1–IVA)…
NCT02405221 - New trial
Cervical and other gynecologic cancers
Phase 4 TIVDAK tissue factor–directed antibody-drug conjugate ocular safety trial
This study by Pfizer evaluates ocular side effects in patients with recurrent/metastatic cervical cancer post-chemotherapy. Eligible participants have no active eye issues and are TIVDAK-naïve, with scheduled eye…
NCT06952660 Exploratory - New trial
Cervical and other gynecologic cancers
Phase II Investigational HDR Brachytherapy (dose-adjusted internal radiotherapy) in cervical cancer.
This prospective non-randomized trial from Stanford University in Palo Alto evaluates a 3-fraction versus standard 4-fraction HDR brachytherapy regimen in locally advanced cervical cancer. Patients meeting dosimetric…
NCT07022470 Exploratory - Trial result
Cervical and other gynecologic cancers
Induction Chemotherapy Enhances Survival in Locally Advanced Cervical Cancer
In the INTERLACE phase 3 trial involving 500 patients, adding a short-course induction regimen of carboplatin and paclitaxel to standard cisplatin-based chemoradiotherapy significantly improved 5-year…
- New trial
Cervical and other gynecologic cancers
Phase II DURAFAK Trial Combines Dual RAF/MEK and FAK Inhibition in Recurrent Gynecological Cancers
The University of Oklahoma is evaluating the safety and efficacy of VS-6766 (avutometinib) together with defactinib in patients with recurrent endometrioid, mucinous ovarian, high-grade serous ovarian, or solid…
NCT05512208
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.